Lab testing of tumor samples to choose the next treatment in metastatic breast cancer
Tests whether lab-tested tumor samples can guide treatment in hormone receptor-positive metastatic breast cancer.
Plain-language title generated from the registry record
Registry title: Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
Key facts
- Where
- Tel Aviv, IsraelSee the site
Where in Israel
- Tel-Aviv Sourasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT07895160
- Record updated
- 26 October 2026
- Original description
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy.Read full original descriptionShow less
OCEAN: Organ Culture for Endocrine Resistant Next Line - Treatment Selection Based on Fresh Tumor Samples in Metastatic Breast Cancer
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy.
A biopsy sample from each participant will be tested using an ex vivo organ culture (EVOC) platform, which preserves the tumor tissue and allows researchers to assess its response to different anticancer treatments. The results will be used to help select the participant's next systemic treatment.
The main objective is to evaluate the proportion of patients whose cancer responds to treatment selected using this approach. The study will also assess how long the cancer remains controlled, overall survival, and the relationship between laboratory test results and clinical outcomes.
Inclusion: Patients progressing on endocrine therapy, with or without biological therapy, who are candidates for their first non-endocrine-based line of treatment; Patients expected to receive treatment for metastatic breast cancer within the coming weeks; Age 18 years or older; Life expectancy of at least 3 months; Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Exclusion: Chemotherapy within 3 weeks before biopsy or aspiration; Any severe concurrent disease that, in the investigator's judgment, makes the patient unsuitable for study participation; Treatment with another investigational drug within 14 days before study entry; Positive test for acquired immunodeficiency syndrome (AIDS); Positive hepatitis B or hepatitis C testing indicating acute or chronic infection; Pregnancy or breastfeeding; Inability to exercise judgment.